Associated Genetic Biomarkers
NCI Definition: A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO) 
Papillary craniopharyngiomas most frequently harbor alterations in BRAF, NOTCH1, KMT2D, CTNNB1, and CADM2 .
BRAF V600E, BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, and NOTCH1 P1443L are the most common alterations in papillary craniopharyngioma .
There is 1 clinical trial for papillary craniopharyngioma, of which 1 is open and 0 are completed or closed. Of the trial that contains papillary craniopharyngioma as an inclusion criterion, 1 is phase 2 (1 open).
BRAF is the most frequent gene inclusion criterion for papillary craniopharyngioma clinical trials .
Cobimetinib and vemurafenib are the most common interventions in papillary craniopharyngioma clinical trials.
Significant Genes in Papillary Craniopharyngioma
BRAF is altered in 100.0% of papillary craniopharyngioma patients .
BRAF is an inclusion eligibility criterion in 1 clinical trial for papillary craniopharyngioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and papillary craniopharyngioma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.